Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1066)	3/10/2006 4:49:16 PM
From: quidditch	Read Replies (1) \| Respond to of 1255

I understand that he was consulted on the screenplay for "The Constant Gardener" and for Bianco's conference presentations on xyotax (pre-release of results).

To: Icebrg who wrote (1066)	3/10/2006 5:12:09 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 1255

Erik: Maybe so, but: Roger Stoll-when making reference to Goteborg's Arvid Carlsson, said that Carlsson's expectation of glutamatergic efficacy in schizophrenia was being borne out--which would lead many, Urko perhaps among them, to interpret this as indicating confidence in Organon's monotherapy trial. Given Goff's results with CX516 (albeit in combo tx), I've been optimistic too. Secondly--by definition, a novel treatment being used as a monotherapy is only going to be given to treatment-refractory schizophrenics, it would be unethical to do otherwise. Thus 'Urko's statement that the best results would be seen among refractory patients is a nonstatement--no nonrefractory patients are even included. So, the fact he said that makes me think he has no 'tradecraft', only the ability to listen to a conference call and a smattering of psychiatric lingo. Perhaps I have become overly cynical. Regards, Harry NeuroInvestment